MAY 29, 2019 3:05 AM PDT

Novel Gene Therapy Approved by FDA to Treat Spinal Muscular Atrophy in Pediatric Patients

WRITTEN BY: Dena Aruta

The most common form of spinal muscular atrophy (SMA), a rare genetic disease, is caused by mutations of chromosome 5 in the gene, SMN1. SMN1 encodes for the protein, SMN, which translates to "survival of motor neuron." SMN appears to be responsible for the normal function of motor neurons in the spine that control voluntary muscle activity. Nearby SMN2 genes, depending on the number present, can partially compensate for the lack of SMN1 genes. There is also a rare form that is non-chromosome 5-linked SMA.

The majority of the symptoms these patients experience are related to muscle weakness in muscles near the center of the body (shoulders, thighs, upper back, hip). When the muscles involved in breathing and swallowing are affected, the prognosis is poor, resulting in death before two years of age. Due to the high variability in the age when symptoms begin, chromosome 5 SMA is broken down into four types ranging from mild to severe. Type 1 is seen at birth or in infancy and has the poorest prognosis. Types 2 and 3 develop during childhood and type 4 in teens and adults. Patients who develop SMA later in their teens or adulthood have milder and better motor functioning. The age of onset depends on the amount of functioning SMN the patient has, which correlates with the amount of SMN2 genes; the more functioning SMN, the later the onset.

There are currently no cures for SMA; however, on May 24, 2019, the FDA approved a novel gene therapy drug, Zolgensma, to treat SMA in children under two years of age. It is an adenovector-based gene therapy that targets the SMN1 gene and replaces it with a fully functioning copy into the affected motor neurons.

Figure 1. Example of Adenovector-Related Gene Therapy. Credit: National Human Genome Research Institute

Infants receiving this treatment require a one-time IV dose based on their weight. Its effectiveness has been evaluated in one completed clinical trial and one that is ongoing. Significant improvement in meeting milestones such as the ability to sit up without support has been reported in infants with SMA when compared to those not receiving the treatment.  The most common side effect is liver damage, which has to be monitored for at least three months after the procedure.

The FDA pushed Zolgensma through as a fast track, breakthrough therapy designated as priority review and an orphan drug. It also awarded the manufacturer, AveXis, Inc., with a rare pediatric disease voucher. There are few treatments available for some rare pediatric diseases, and these programs have been set up by the FDA to encourage research to find better treatments or cures for those diseases that currently have few options. 

 

 

About the Author
  • After earning my Bachelor of Science degree in biology/chemistry from Virginia Polytechnic Institute and State University (aka Va. Tech), I went on to complete clinical rotations in laboratory medicine at Roanoke Memorial Hospital. I spent the next 21 years working in healthcare as a clinical microbiologist. In 2015, I combined my fascination with medicine and passion for writing into a freelance career, and I haven't looked back. Even though my expertise is in microbiology and infectious diseases, I'm adept at writing about any medical topic. Being a freelance writer allows me to pursue a career where I can work at home with my two feline assistants, Luke and Grace. I'm a firm supporter of animal rights and volunteer for a local rescue during my free time. 
You May Also Like
DEC 29, 2020
Microbiology
How CRISPR Can Help Create a Vaccine for a Common Parasite
DEC 29, 2020
How CRISPR Can Help Create a Vaccine for a Common Parasite
The parasite Toxoplasma gondii is thought to infect a third of the people on the planet as well as a wide range of other ...
DEC 31, 2020
Clinical & Molecular DX
Silent Mice Drive Autism Gene Discovery
DEC 31, 2020
Silent Mice Drive Autism Gene Discovery
Around 1 in 54 children in the U.S. are diagnosed with autism spectrum disorder, or ASD, a broad range of conditions tha ...
JAN 01, 2021
Genetics & Genomics
Common Brain Disorder Has a Genetic Influence
JAN 01, 2021
Common Brain Disorder Has a Genetic Influence
It's thought that as many as one in one hundred people are born with a brain disorder known as Chiari 1 malformation, bu ...
JAN 12, 2021
Immunology
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
JAN 12, 2021
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
The first organ transplant—performed over 60 years ago—was a success because the donor and recipient were id ...
JAN 17, 2021
Cell & Molecular Biology
How a Nutrient Can Aid in Infection Prevention
JAN 17, 2021
How a Nutrient Can Aid in Infection Prevention
Antibiotic-resistant microbes are considered to be a serious threat to public health, one of many reasons why it's impor ...
JAN 21, 2021
Health & Medicine
Injectable Cannabis Overdose Drug Being Developed
JAN 21, 2021
Injectable Cannabis Overdose Drug Being Developed
It’s estimated that the number of visits to emergency rooms because of cannabis overdose tripled between 2011 and ...
Loading Comments...